Opus Genetics (IRD) Operating Leases (2019 - 2020)
Opus Genetics' (IRD) quarterly Operating Leases came in at $25790.0 in Q1 2020, down 85.79% year-on-year from $181490.0 in Q2 2019, and down 59.45% on a QoQ basis from $63605.0 in Q4 2019.
Opus Genetics (IRD) Operating Leases (2019 - 2020) Analysis & Trends
Opus Genetics (IRD) has 2 years of Operating Leases data on file, last reported at $25790.0 in Q1 2020.
- On a quarterly basis, Operating Leases fell 85.79% year-over-year to $25790.0 in Q1 2020; TTM through Mar 2020 was $25790.0, a 85.79% decrease from a year earlier, with the FY2019 full-year figure at $63605.0, changed N/A from the prior year.
- Operating Leases for Q1 2020 stood at $25790.0, down from $63605.0 in the prior quarter.
- Over the last five years, Operating Leases for IRD reached as high as $181490.0 in Q1 2019 and fell as low as $25790.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 25,790.00 |
| Dec 31, 2019 | 63,605.00 |
| Sep 30, 2019 | 100,397.00 |
| Jun 30, 2019 | 136,196.00 |
| Mar 31, 2019 | 181,490.00 |